FDA’s March 2026 wave: 30 telehealth warning letters explained
A plain-English read on what was flagged, what it changes, and what it does not.
TL;DR
- The FDA sent warning letters to roughly 30 telehealth companies in March 2026 over compounded GLP-1 marketing and prescribing.
- The letters target sales practices and clinical workflows — not compounding itself.
- For patients, the practical takeaway is to ask whether your provider does a real evaluation and discloses risks honestly.
What it is
The Food and Drug Administration (FDA) sent enforcement notices — called warning letters (in plain English: formal notes telling a company that specific practices appear to break federal rules) — to about 30 telehealth companies in March 2026 (FDA Newsroom, 2026). A warning letter is not a fine and not a ban. It is the agency saying “fix this, or we will escalate.” Most letters in this wave centered on how telehealth firms market and prescribe compounded GLP-1 products such as compounded semaglutide and compounded tirzepatide.
How it works
Think of a warning letter as a yellow card in soccer. The FDA flags a problem, names it, and gives the company a short window — usually 15 working days — to respond. The agency then decides whether the company’s response is enough or whether to escalate to seizure, injunction, or other enforcement. The March 2026 wave called out three patterns: marketing language that overstated benefits, missing risk information about side effects like nausea and pancreatitis, and prescribing workflows the FDA judged too thin to count as a real clinician evaluation (FDA Newsroom, 2026).
Who asks about it
People come to this topic after a headline scares them and they want to know if their program is suddenly illegal. The honest answer: receiving a letter is not the same as being shut down. The FDA is naming specific practices — and most companies adjust within weeks.
What the research says
Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients (FDA Compounding Q&A, 2024). The compounding itself is legal under specific conditions. The March 2026 letters did not declare compounded GLP-1 illegal. They focused on marketing claims and clinical workflows, mirroring the February 2026 enforcement wave.
What to know before considering it
If you use a telehealth program for compounded GLP-1, ask three things: does a licensed clinician actually evaluate you, are side effects disclosed in writing, and is the pharmacy state-licensed and identifiable. Compounded GLP-1 products are also the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, February 2026).
The Halftime POV
Warning letters are imperfect signals — but they are signals. The pattern in 2026 is clear. The FDA is policing how telehealth markets and prescribes, not whether compounded medications can exist. That is the right place for the agency to focus, and it is the same place we focus when we choose partners.
Related reading:
- FDA’s February 2026 warning letter wave: what happened
- Novo Nordisk v. Hims & Hers: the compounded GLP-1 case
- Compounded semaglutide: what it is and how it differs from branded
FAQ
Q: What is an FDA warning letter? A: An FDA warning letter is a formal notice from the agency telling a company that specific practices appear to break federal rules. It is not a fine and not a ban. The company is given a short window to respond and correct the issue before the FDA decides whether to escalate.
Q: Are compounded GLP-1 medications illegal after the 2026 letters? A: No. Compounded GLP-1 medications prepared by state-licensed 503A pharmacies from FDA-approved active ingredients remain legal under specific conditions. The 2026 letters focused on marketing claims and prescribing workflows at telehealth companies, not on compounding itself.
Q: What did the FDA flag in the March 2026 letters? A: The agency described three patterns: marketing language that overstated benefits, missing risk information about side effects like nausea and pancreatitis, and prescribing workflows the FDA judged too thin to count as a real clinician evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
